.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,431,154

« Back to Dashboard

Claims for Patent: 8,431,154

Title:Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
Inventor(s): Dietrich; Rango (Constance, DE), Eistetter; Klaus (Constance, DE), Ney; Hartmut (Constance, DE)
Assignee: Takeda GmbH (Constance, DE)
Application Number:13/008,842
Patent Claims: 1. A dosage form for oral administration of a PDE 4 inhibitor produced by the process comprising the steps: (a) producing a mixture of a PDE 4 inhibitor of formula I ##STR00002## in which R1 is difluoromethoxy, R2 is cyclopropylmethoxy and R3 is 3,5-dichloropyrid-4-yl, or a salt of this compound, or an N-oxide of the pyridine of this compound or a salt thereof, and one or more pharmaceutical excipients; and (b) granulating the mixture obtained in (a) with an aqueous solution of polyvinylpyrrolidone; wherein the dosage form is in tablet or pellet form and wherein said dosage form provides immediate release of the PDE 4 inhibitor.

2. The dosage form of claim 1, further comprising: (a) drying the granules, (b) optionally admixing other pharmaceutical excipients, (c) mixing with a release agent and (d) compressing in a tablet press.

3. The dosage form according to claim 1; wherein the granulating takes place in a fluidized bed granulator.

4. The dosage form according to claim 1, wherein in step (a) the PDE 4 inhibitor is admixed with the one or more pharmaceutical excipients in the form of a trituration with a pharmaceutical excipient.

5. The dosage form according to claim 4, which trituration is obtained by grinding the PDE 4 inhibitor with the one or more pharmaceutical excipients.

6. The dosage form according to claim 4, wherein the pharmaceutical excipient is a filler.

7. The dosage form according to claim 1, comprising granulating a mixture of (a) a PDE 4 inhibitor of formula I, or a trituration of a PDE 4 inhibitor of formula I with corn starch, (b) corn starch and (c) lactose monohydrate with an aqueous polyvinylpyrrolidone solution to form granules, drying the granules, mixing the granules with a release agent and compressing the granules in a tablet press.

8. The dosage form according to claim 1, comprising granulating a mixture of (a) PDE 4 inhibitor of formula I, or a trituration of a PDE 4 of formula I with corn starch, (b) corn starch, (c) microcrystalline cellulose and (d) sodium carboxymethylstarch with an aqueous polyvinylpyrrolidone solution to form granules, drying the granules, mixing the granules with a release agent and compressing the granules in a tablet press.

9. A dosage form for oral administration of a PDE 4 inhibitor produced by the process comprising the steps: (a) producing a mixture of pharmaceutical excipients; and (b) granulating the mixture obtained in (a) with a suspension of a PDE 4 inhibitor of formula I, ##STR00003## in which R1 is difluoromethoxy, R2 is cyclopropylmethoxy and R3 is 3,5-dichloropyrid-4-yl or a salt of this compound, or an N-oxide of the pyridine of this compound or a salt thereof, in an aqueous solution of PVP, wherein the dosage form is in tablet or pellet form and wherein said dosage form provides immediate release of the PDE 4 inhibitor.

10. The dosage form according to claim 9, comprising granulating a mixture of corn starch and lactose monohydrate with a suspension of a PDE 4 inhibitor of formula I in an aqueous solution of PVP to form granules, drying the granules, mixing the granules with a release agent and compressing the granules in a tablet press.

11. A dosage form for oral administration of a PDE 4 inhibitor produced by the process comprising the steps: (a) producing an active ingredient preparation in the form of a solid solution in polyvinylpyrrolidone of a PDE 4 inhibitor of formula I, ##STR00004## in which R1 is difluoromethoxy, R2 is cyclopropylmethoxy and R3 is 3,5-dichloropyrid-4-yl, or a salt of this compound, or an N-oxide of the pyridine of this compound or a salt thereof; (b) producing a mixture of an active ingredient preparation and pharmaceutical excipients and (c) granulating the mixture obtained in (b) with an aqueous solution of polyvinylpyrrolidone; wherein the dosage form is in tablet or pellet form and wherein said dosage form provides immediate release of the PDE 4 inhibitor.

12. The dosage form according to claim 9 in the form of a tablet, wherein the granules obtained in step (b) are dried, mixed with lubricants or release agents and compressed in a tablet press.

13. The dosage form according to claim 9 wherein the pharmaceutical excipient is a filler.

14. The dosage form according to claim 9, wherein the PVP is selected from the group consisting of polyvinylpyrrolidone of the weight average molecular weight 28,000-34,000, polyvinylpyrrolidone of the weight average molecular weight 44,000-54,000 and polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000.

15. The dosage form according to claim 9, wherein the PDE 4 inhibitor is N-(3,5-dichloropyrid-4-yl)-3 cyclopropylmethoxy-4-difluoromethoxy benzamide (roflumilast).

16. The dosage form according to claim 9, wherein the PDE 4 inhibitor is the N-oxide of the pyridine of the compound of formula I.

17. The dosage form according to claim 10, containing from 0.01 mg to 5 mg of roflumilast per dosage unit.

18. The dosage form according to claim 9, wherein the proportion of polyvinylpyrrolidone is from 1 to 5% by weight.

19. The dosage form according to claim 9, wherein the proportion of polyvinylpyrrolidone is from 2 to 3% by weight.

20. The dosage form according to claim 9, where the pharmaceutical excipients are excipients selected from the group consisting of fillers, additional binders, tablet disintegrants, lubricants, release agents, flavouring substances, buffer substances, preservatives, coloring substances and emulsifiers.

21. The dosage form according to claim 9, wherein the proportion of all binders present is from 0.5 to 20% by weight.

22. The dosage form according to claim 20, which is a tablet and wherein the proportion of filler is from 40 to 99% by weight.

23. The dosage form according to claim 20, wherein the filler is selected from the group consisting of sugar alcohols, starches, saccharides and mixtures thereof.

24. The dosage form according to claim 23, wherein the filler is selected from the group consisting of corn starch, microcrystalline cellulose, lactose and mixtures thereof.

25. The dosage form according to claim 20, wherein the lubricant or release agent is selected from the group consisting of sodium stearyl fumarate, magnesium stearate, calcium stearate, stearic acid, talc and colloidal anhydrous silica.

26. The dosage form according to claim 9, wherein the pharmaceutical excipients are at least one filler and at least one lubricant or release agent.

27. The dosage form according to claim 9, comprising: (a) Roflumilast 0.125 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.

28. The dosage form according to claim 9, comprising: (a) Roflumilast 0.250 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.

29. The dosage form according to claim 9, comprising: (a) Roflumilast 0.500 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.

30. The dosage form according to claim 9, further comprising producing a solid solution of the PDE 4 inhibitor in the PVP as carrier.

31. The dosage form according to claim 30, wherein the solid solution is a solid solution with amorphous structure, in which the PDE 4 inhibitor is in the form of a molecular dispersion in the carrier material.

32. The dosage form according to claim 9, wherein said granulating step (b) is conducted in a fluidized bed granulator.

33. The dosage form according to claim 1, comprising: (a) Roflumilast 0.125 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.

34. The dosage form according to claim 1, comprising: (a) Roflumilast 0.250 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.

35. The dosage form according to claim 1, comprising: (a) Roflumilast 0.500 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.

36. The dosage form according to claim 11, comprising: (a) Roflumilast 0.125 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.

37. The dosage form according to claim 11, comprising: (a) Roflumilast 0.250 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.

38. The dosage form according to claim 11, comprising: (a) Roflumilast 0.500 mg (b) Lactose monohydrate 49.660 mg (c) Corn starch 13.390 mg (d) Polyvinylpyrrolidone of the weight average molecular weight 1,000,000-1,500,000 1.300 mg; and (e) Magnesium stearate (vegetable) 0.650 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc